PharmaFocus Today – Page 205 – media

Cutting-Edge Lab Automation System Supports High-Volume Needs and Provides Faster Results

A new, innovative automation solution for clinical labs featuring smart technology can boost lab performance and flexibility, reduce turnaround time, and eliminate 80% of manual steps, thereby increasing reliability and minimizing errors to provide quicker lab results Abbott’s (Lake Forest, IL, USA) GLP systems Track is a cutting-edge technology and scalable automation solution that helps laboratories meet high-volume demand and maximize productivity. This system introduces innovative features that boost safety, productivity, and capacity to meet increasing laboratory demands. The flexibility of the GLP systems Track is a standout feature, offering laboratories the ability to tailor the system’s configuration to their specific requirements. A key innovation in this system is the CAR, a smart, self-propelled single sample carrier, which allows samples to move independently, not attached to rigid, fixed mechanized track systems. This innovation minimizes mechanical breakdowns that could halt operations, ensuring continuous functionality and adaptability to the lab’s evolving needs. ...
- Source: drugdu
- 105
- December 21, 2023
Gene Therapy and a New Medicine Delivery Approach Signal Progress for Cystic Fibrosis Patients

It’s time to build the infrastructure needed to scale up inhaled gene therapies targeting cystic fibrosis, and to bolster investment that supports several key program components. By JOAN LAU Thanks to simultaneous achievements in gene therapy and medicine delivery platforms, new solutions to intractable problems are bringing us to a real watershed moment in the treatment of respiratory disease. This synchronicity of science and tech advancements is no accident; along with colleagues in my own and other organizations, I have been working for the past several years on the medical and technological leaps that together signal hope for respiratory-disease patients with unmet need. This is especially true for those with cystic fibrosis (CF), for whom the standard of care is in urgent need of update. And now that we have the science and the technology in place, we must push to scale-up efforts; patients are waiting. Right now, CF patients ...
- Source: drugdu
- 95
- December 21, 2023
Chiesi Rare Skin Disease Drug Acquired in Billion Dollar Deal Wins FDA Approval

Chiesi Group’s Filsuvez is the second drug to win FDA approval for epidermolysis bullosa and the first for junctional EB, a more severe form of the rare skin disease. The birch tree bark-derived drug is from Chiesi’s $1.25 billion Amryt Pharma acquisition. By FRANK VINLUAN The rare inherited disorder epidermolysis bullosa, or EB, leads to skin so fragile that it tears like tissue paper. The resulting wounds and blisters are slow to heal and prone to infection. On Tuesday, the FDA approved a Chiesi Group drug developed to promote faster wound healing in EB patients. Privately held Chiesi will market its new drug as Filsuvez, the same brand name for the product in Europe, where it won its first regulatory approval last year. The FDA decision for this topical gel covers the treatment of patients age six months and older. EB stems from a mutation to the gene that codes ...
- Source: drugdu
- 99
- December 21, 2023
reminder on known risk of gambling disorder

The MHRA has reminded healthcare professionals prescribing aripiprazole to be alert to the known risk of patients developing addictive gambling, following a rise in the number of reports received in 2023 Aripiprazole is an important medicine for the treatment of schizophrenia and bipolar disorder. Patients are advised to tell their doctor if they or their family and friends notice they are having unusual urges or cravings that they cannot resist, including behaviours such as addictive gambling, excessive eating or spending, or an abnormally high sex drive. Patients should continue taking aripiprazole as advised. Stopping aripiprazole without medical advice can be harmful. In the last 14 years, the MHRA’s Yellow Card scheme received 69 reports of gambling or gambling disorder where aripiprazole was suspected to be the cause. Thirty-two of these reports were received between 1 January and 31 August this year. In March 2023, the MHRA asked gambling clinics to ...
- Source: drugdu
- 86
- December 21, 2023
After missing out on FDA voucher, bluebird quickly raises funds to support gene therapy launches

Despite bluebird bio winning a recent FDA nod for its much-anticipated sickle cell disease gene therapy Lyfgenia, the regulatory triumph left something to be desired for the company because the agency didn’t grant a lucrative priority review voucher (PRV). That came as a surprise to bluebird, which had previously inked a deal to sell a potential PRV to Novartis for $103 million. Now, bluebird is hurrying to raise millions of dollars—through two separate avenues—to fund the launch of its new sickle cell disease gene therapy and others. In one fundraising approach, bluebird said it reached an agreement to hand over future gene therapy revenues to Alterna Capital Solutions in exchange for up-front funding. The deal covers a maximum credit of $100 million for bluebird, the company said in an SEC filing (PDF). Additionally, bluebird is working with Goldman Sachs and J.P. Morgan Securities to sell $150 million in new shares. ...
- Source: drugdu
- 97
- December 21, 2023
Amid BioNTech legal fight, CureVac takes a loss as German court invalidates patent

A German court has dealt the first blow against CureVac amid the company’s heated COVID-19 vaccine patent fight with fellow German mRNA specialist BioNTech. The German Federal Patent Court ruled that one of eight CureVac patents involved in the litigation is invalid, the company said in a Tuesday release. The patent in question covers a process that improves the expression of mRNA in cells, Juve Patent reports. The ruling came as a surprise to CureVac, which noted that the court in April issued a preliminary opinion in favor of the patent’s validity. Still, CureVac believes its “pioneering role in mRNA technology and continuing innovation in the field made essential contributions to safe and efficacious COVID-19 vaccines,” CEO Dr. Alexander Zehnder said in a statement. The company will “continue to defend our claim for recognition and fair compensation and will take appropriate action by appealing this decision,” Zehnder added. CureVac’s appeal ...
- Source: drugdu
- 93
- December 21, 2023
Signing ceremony between the Municipality of Bogotá, Colombia and SINOVAC for the official launch of the joint venture BogotáBio

On December 18th, local time in Colombia, a signing ceremony was held between the Municipality of Bogotá and SINOVAC. Claudia López Hernández, Mayor of Bogota, and Weidong Yin, Chairman, President and CEO of SINOVAC, signed the cooperation agreement on behalf of the two parties for the Bogota Vaccine Plant Project and announced the official launch of BogotáBio, a joint venture company jointly funded by the two parties. The Bogotá Vaccine Factory project will promote the localized production of a variety of vaccines in Colombia as well as the research and development of new vaccines and innovations, thereby enhancing the local capacity to respond to infectious diseases and prepare for the next pandemic. The signing ceremony was attended by Colombian Foreign Minister Álvaro Leyva Durán, Chinese Ambassador to Colombia Zhu Jingyang, Colombian Deputy Minister of Trade, Industry and Tourism Quintero, and nearly 60 guests from the Colombian central government, Bogota city ...
- Source: drugdu
- 145
- December 21, 2023
The First Da Vinci Xi Surgical Robot Made in China Officially “Onboarded”, Making High-Quality Medical Resources More Accessible

On December 18, the start-up ceremony of the Da Vinci surgical robot was successfully held in Gansu Hospital, Affiliated Cancer Hospital of Sun Yat-sen University. This marks that the first domestic Da Vinci Xi surgical robot has officially settled in Gansu Hospital of Sun Yat-sen University Cancer Hospital, helping the construction of the national regional medical center, bringing more efficient, accurate and safer surgical treatments to the majority of patients, and marking the commercialization of the domestic Da Vinci surgical robot into the era. After the launching ceremony, the Da Vinci Xi surgical robot was formally “on duty” in the operating room of Gansu Hospital, Affiliated Cancer Hospital of Sun Yat-sen University. With the assistance of the surgical robot, Executive Director Prof. Liu Zhuowei’s team successfully performed “robot-assisted partial nephrectomy” for the patient. Prof. Liu Zhuowei introduced that the surgical robot makes the surgical incision smaller, less painful, shortens the ...
- Source: drugdu
- 104
- December 21, 2023
Smartwatches prove effective in detecting heart arrhythmias in children

A recent study published in the journal Communications Medicine discusses how smartwatches can facilitate the diagnosis of arrhythmias in children. Background Smartwatches and other wearable devices are becoming increasingly popular and allow users to constantly monitor their health, leading to their value for medical diagnosis becoming well-recognized. While the utility of these devices for adults has been widely researched, including for cardiac health monitoring and reducing the time needed to detect symptomatic rhythms, little is known about how they can be used to monitor child health indicators. Palpitations and abnormalities in cardiac rhythms are a leading cause of referrals in pediatric cardiology. However, existing non-invasive methods like patch rhythm monitors are not always effective in diagnosing arrhythmias, as symptoms often present infrequently, and children cannot wear monitors for as long as adults. Invasive methods such as implantable loop monitors (ILR) allow long-term monitoring. However, this approach may not be ideal ...
- Source: drugdu
- 110
- December 20, 2023
Fluorescence Microscopy Combined with AI Enables Detection of Tumors at Early Stage

Detecting cancer in the body or monitoring it during therapy is typically a time-consuming process, often conducted in later phases when signs become obvious. Researchers engaged in cancer research are continuously seeking reliable and sensitive techniques to detect a developing tumor at a very early stage and to closely monitor the success or failure of cancer therapy. Therefore, a breakthrough in early cancer diagnosis is a significant advancement. Researchers have now achieved a breakthrough with the development of a test for early diagnosis of cancer. Researchers at the Paul Scherrer Institute (Würenlingen, Switzerland) have demonstrated that changes in the organization of the cell nucleus of certain blood cells can reliably indicate the presence of a tumor in the body. Using fluorescence microscopy, the team examined the chromatin of these blood cells – DNA packaged into a complex structure. They analyzed about 200 different characteristics, including the external texture, the packing ...
- Source: drugdu
- 111
- December 20, 2023

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.